Hemophilia A With Inhibitor

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors

Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

ATHN 7: Hemophilia Natural History Study

The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A

An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families

SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment

Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem

Pharmacokinetic-guided Dosing of Emicizumab

A Phase I of SS109 in Hemophilia A or and B With Inhibitors

The Hemophilia Inhibitor Eradication Trial

ATHN 8: Previously Untreated Patients (PUPs) Matter Study

Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors

A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab

Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders